Videos

  Clinical Conversations by Experts View all

ASCO 2026

AUA 2026

APCCC 2026

PSMA and Beyond 2026 Conference

Featured Videos

PROTEUS Trial: Neoadjuvant Apalutamide and Androgen Deprivation Therapy in High-Risk Localized Prostate Cancer - Mary-Ellen Taplin
Large-Scale Data Linkage Reveals Genomic Differences in De Novo Metastatic Prostate Cancer - Shalini Moningi
PTEN Loss and the Future of Precision Treatment in mHSPC - Karim Fizazi & Noel Clarke
Cohort P Data from the BOND-003 Study in BCG-Unresponsive Papillary Bladder Cancer - Mark Tyson
ZIRCON-X: CAIX PET Imaging and Its Role in Biopsy, Surgery, and Care Planning for Indeterminate Renal Masses - Brian Shuch
24-Month Follow-Up Data from Phase 3 BOND-003 Cohort C Trial - Mark Tyson
CORE-008 Cohort B Investigates Cretostimogene Grenadenorepvec for BCG-Exposed High-Risk NMIBC - Trinity Bivalacqua
Shifting From TURBT to Chemoablation in Low-Grade Intermediate-Risk NMIBC - Max Kates
Real-World Experience With the Expanded Access Program for 89Zr-Girentuximab PET in Small Renal Masses - R. Jonathan Henderson
OPTIMA II Five-Year Data: Mitomycin Chemoablation Provides Durable Response in LG-IR-NMIBC - Neal Shore
CAPItello-281: Targeting the AKT Pathway in PTEN-Deficient mHSPC Presentation - Daniel George
Analysis of Genomic Drivers of Discordant Risk Classifications in Prostate Cancer - Michael Zelefsky
NRG-GU006 Trial for Post-Prostatectomy Radiation Therapy - Daniel Spratt
Validating the APUC-6 Signature in mHSPC from the ECOG-ACRIN E3805 CHAARTED Trial - Xiaolei Shi
Phase I Study of SYNC-T Combination Therapy for Metastatic Castration-Resistant Prostate Cancer - Jason Hafron
ZUSDURI™ FDA Approved for Low-Grade Intermediate-Risk Bladder Cancer - Mark Schoenberg
Expanding Treatment Options: FDA Approval of Mitomycin Intravesical Solution for Recurrent Low-Grade Intermediate-Risk NMIBC - Sandip Prasad
Exploring Immunotherapy Outcomes in Cisplatin-Ineligible Bladder Cancer - Michiel Van Der Heijden
FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer - Neal Shore
Genomic and Clinical Profiles of Rapidly Progressing mCRPC Patients - Maha Hussain
PDIGREE Trial Tests Adaptive Immunotherapy Approach for Metastatic Kidney Cancer - Tian Zhang
Complete Response in Low-Grade UTUC with Padeliporfin Therapy in the ENLIGHTED Trial - Vitaly Margulis
CORE-008 Cohort B: Cretostimogene for BCG-Exposed NMIBC – Trial Activation & Clinical Goals - Trinity Bivalacqua
Evaluating Risk Stratification Models for Blue Light Cystoscopy in Bladder Cancer - Sia Daneshmand & Boris Gershman
Streamlining Intravesical Therapy: Practical Insights for BCG-Unresponsive NMIBC - Patrick Hensley
Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines - Jay D. Raman & Yair Lotan
Refining Risk in NMIBC: Intermediate Stratification, TURBT Quality, and Emerging Options - Katie Murray
The Details Are in the Core: Advancing Prostate Tissue Collection - James Wysock
EMBARK Trial: Treatment Options for High-Risk Biochemical Recurrence - Neal Shore
First Patient Treated with Pluvicto™ in Pre-Chemotherapy Setting Following FDA Approval - Steven Finkelstein
Cretostimogene Grenadenorepvec Complete Response in BOND-003 Cohort C - Trinity Bivalacqua
LEGEND Trial: EG-70 in BCG-Refractory Non-Muscle Invasive Bladder Cancer - John Taylor
FDA Approval of 177Lu-PSMA-617 for Taxane-Naive mCRPC - Oliver Sartor
A Case-Based Discussion on First-Line EV + Pembrolizumab for Metastatic Urothelial Carcinoma - Neal Shore
ENVISION Trial Evaluates UGN-102 for Recurrent Low-Grade NMIBC Bladder Cancer - Sandip Prasad
PREDICT Trial Investigates Biomarker-Guided Treatment for Advanced Prostate Cancer - Rana McKay
Advanced Imaging for Focal Therapy in Intermediate Risk Prostate Cancer - Matthew Cooperberg
Revisiting HER2 as a Therapeutic Target in Prostate Cancer - Nicole Mavingire
Real-World Data on Treatment Patterns After PSMA-Targeted Therapy in mCRPC - Oliver Sartor
Phase II ENZA-p Trial Explores Effect of Lutetium PSMA With Enzalutamide - Louise Emmett
Cretostimogene Grenadenorepvec Expanded Access Program for BCG-Unresponsive Bladder Cancer - Sarah Psutka
Real-World Safety Profiles of First-Line Therapies for Advanced Urothelial Carcinoma - Amanda Nizam
Adjuvant Nivolumab in High-Risk Muscle Invasive Bladder Cancer Analysis Shows Improved Outcomes for Patients: CheckMate 274 - Matthew Galsky
Registry Data Shows Risk Migration With Blue Light Cystoscopy - Alireza Ghoreifi & Siamak Daneshmand
ARANOTE Trial Explores Darolutamide’s Role in High and Low-Volume Metastatic Prostate Cancer - Fred Saad
Real-World Data on Nadofarogene Firadenovec for BCG-Unresponsive Bladder Cancer - Mark Tyson & Jacob Moyer
Physician Decision Making & Combination Therapies in Metastatic Prostate Cancer - Neeraj Agarwal
Nectin-4 Expression Not Predictive of Response in Enfortumab Vedotin Therapy - Thomas Powles
Advancing Imaging Techniques for Indeterminate Renal Mass Diagnosis and Clinical Decision-Making - Sam Chang
CLARIFY Trial: Multiday 64Cu-SAR-bisPSMA PET Scans Refine Prostate Cancer Assessment - Luke Nordquist
RISE FOR HEALTH Study on Female Bladder Health - Ariana Smith
Utilizing Telehealth to Improve Access of Care of Patients with Bladder Cancer - Tracey Krupski
Integrating Genomic Testing with MRI Enhances Stratification of Surveillance Patients - Eric Kim & Mark Sultan
Advancing Treatment for BCG-Unresponsive Bladder Cancer - Eugene Pietzak
PIVOT-006: Phase III Trial of Creto vs Surveillance in Intermediate-Risk Bladder Cancer - Mark Tyson
Emerging Neoadjuvant Combinations for Muscle-Invasive Bladder Cancer - Mamta Parikh
BCG Unresponsive Bladder Cancer in 2024 - Ashish Kamat
BOND-003 Trial Results in BCG Unresponsive Non-muscle Invasive Bladder Cancer - Mark Tyson
5-Year Survival Outcomes in Cisplatin-Ineligible Patients from EV-103 - Jonathan Rosenberg
Radium-223 Plus Enzalutamide Improves Survival in mCRPC: PEACE-3 Trial Results, Journal Club - Rashid Sayyid & Zachary Klaassen
BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence - Ali Nasrallah
Belzutifan vs Everolimus Trial Data in Advanced RCC Care - Brian Rini
AI-Powered Prostate Cancer Risk Assessment Tool Validated for Low-risk and Active Surveillance - Andre Esteva
SWOG Trial On Standard vs Extended Lymphadenectomy in Muscle Invasive Bladder Cancer - Seth Lerner
NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles
Advancing mHSPC Treatment Options: ARANOTE Trial Analysis - Neal Shore & Fred Saad
Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard
Radiation Therapy Options for Localized Prostate Cancer Compared in Major Trial - Jason Efstathiou
PEACE-3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad
Proton Therapy vs IMRT in Prostate Cancer PARTIQoL Trial - Jason Efstathiou
SunRISe-1 Trial Advances Bladder Cancer Treatment with TAR-200 - Michiel Van der Heijden
RAPSON Trial Explores Radium223 and Docetaxel Sequencing in mCRPC - Vincenza Conteduca
Darolutamide Improves Outcomes for mHSPC Patients in ARANOTE Trial - Fred Saad
Medicare Part D 2025 Reduces Out-of-Pocket Costs for Oral Prostate Cancer Treatments - David Morris
Financial Distress for GU Cancer Patients: Insights from CDC Survey - Laura Bukavina & Steven Leonard
Cancer-Related Financial Hardship Among Cancer Survivors: Research from the HINTS-SEER Survey - Apoorv Dhir & Rishi Sekar
PARTIQoL Trial: Proton Therapy vs IMRT for Localized Prostate Cancer - Jason Efstathiou
Utilizing the Decipher® mRNA Score for Risk Stratification in mHSPC - David Morris and Ashley Ross
PEACE-3 Trial Results: Radium-223 + Enzalutamide in mCRPC - Bertrand Tombal
UpFrontPSMA Trial: Lutetium-PSMA + Docetaxel in mHSPC - Arun Azad
EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore
ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment - Fred Saad
PEACE-1 Trial Reveals Key Genomic Alterations Linked to Survival in Prostate Cancer Patients - Cédric Pobel
SunRISe-4 Trial Explores TAR-200 and Cetrelimab Combination for Bladder Cancer Treatment - Andrea Necchi
Fecal Microbiota Transplant Boosts Immunotherapy in Metastatic Renal Cell Carcinoma in TACITO-II Trial - Chiara Ciccarese
Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky
PRINCE Trial Highlights Early Detection of Prostate Cancer Progression with PSMA PET-CT - Michael Hofman
COTRIMS Trial Shows High Cure Rates with RPLND in Stage IIA/B Seminoma - Axel Heidenreich
AMBASSADOR Trial: Extended Follow-up on Adjuvant Pembrolizumab in Bladder Cancer - Andrea Apolo
SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment - Oliver Sartor
Genetic Profiles in Early vs. Late Stage Urothelial Cancer - Dag Stormoen
TiNivo-2 Trial Results in Advanced Renal Cell Carcinoma Treatment - Toni Choueiri
Patient Perspectives on Bladder Cancer: Balancing Treatment Options and Shared Decision-Making - Roger Li
Cardiovascular Risks of ARSIs in Prostate Cancer: Meta-Analysis Findings, Journal Club - Rashid Sayyid & Zachary Klaassen
The Rise of FRU: How Functional Urology Intersects with Reconstructive Urology - Brian J. Flynn
Transperineal vs Transrectal Prostate Biopsy: Trial Findings and Discussion - Badar Mian
Robotic Mini-PCNL and Ureteroscopy: Advancing Kidney Stone Treatment "Presentation" - Jaime Landman
Phase 3 CLARIFY Trial Investigates 64Cu-SAR-bisPSMA PET for Improved Prostate Cancer Detection - Louise Emmett
CLARIFY Trial: Advancing Prostate Cancer Imaging with 64Cu-SAR-bisPSMA PET - Neal Shore
COURAGE Trial: Vibegron for BPH Patients with Persistent OAB Symptoms - David Staskin
Advancing RCC Treatment: PROSPER Trial Analysis and Future Directions - Naomi Haas
EV-302 Trial Establishes Treatment Standard for Urothelial Carcinoma - Daniel Petrylak
Overcoming Hormone Resistance: ARV-766 in Advanced Prostate Cancer - Daniel Petrylak
Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff
Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy - Irene Casanova-Salas & Joaquin Mateo
Reservations About a Nomenclature Change for Gleason Grade 1 Prostate Cancer "Presentation" - Adam Kibel
Trimodal Therapy in Urothelial vs Non-Urothelial Bladder Cancer - Mario de Angelis
Cell Surface Targets in mCRPC: Expression Landscape and Therapeutic Potential - Michael Haffner
Urologic Oncology Clinical Trials: Size, Scope, and Impact - Kristian Stensland
2024 NCCN Guidelines Update: Metastatic Castration-Resistant Prostate Cancer Treatment - Rashid Sayyid & Zachary Klaassen
Oxybutynin-Associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment - Beyond the Abstract
Reducing Prescription Drug Costs: 4 Online Tools for Urology Patients - Benjamin Pockros
FGFR3 Inhibition for Upper Tract Urothelial Cancer: Phase 1b Trial Results - Surena Matin
Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results - Yousef Zakharia
PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life - Karim Fizazi
Post-Prostatectomy Care: Variability in Treatment for Lymph Node Positive Prostate Cancer - Daniel Triner
dMMR and MSI-H in Urothelial Carcinoma: Prevalence and Treatment Implications - Elias Chandran
Meta-Analysis Evaluates Cardiovascular Risks of AR Inhibitors in Prostate Cancer - Omar El-Taji & Ashwin Sachdeva
PROSTATE-IQ Trial: Reducing ADT Burden in Salvage Radiotherapy - Karen Hoffman
Functional Renal Imaging and Advances in Kidney Cancer Detection - Shankar Siva
CYCLONE 2 Trial Results: Abemaciclib in Metastatic Castration-Resistant Prostate Cancer - Matthew Smith
Breaking Barriers in Cancer Treatment and Women's Leadership in Oncology - Ulka Vaishampayan
PSCA CAR T-Cell Therapy for Metastatic CRPC: Phase 1 Trial Results - Tanya Dorff
Mental Health and Prostate Cancer in the Veterans Population - Zachary Klaassen
2024 NCCN Guidelines: Simplifying the Management of Very Low-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
Bladder-Sparing Chemoradiation for Localized Bladder Cancer: Addressing the Unmet Need - Brent Rose
SunRISe-5 Trial: Evaluating TAR-200 for Recurrent High-Risk Non-Muscle Invasive Bladder Cancer - Sima Porten
IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer - Stacy Loeb
Machine Learning Model Predicts Overall Survival in Metastatic Prostate Cancer - Ali Sabbagh
Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal
ctDNA Fraction Predicts Response to Lutetium PSMA in TheraP Trial for mCRPC - Edmond Kwan
ARAMIS Trial: PSA Responses with Darolutamide Linked to Minimal Radiographic Progression - Alicia Morgans
Bridging the Gap in Microhematuria Evaluation: A Discussion on the STRATA Trial - Yair Lotan
Prognostic Power of Multi-Modal Artificial Intelligence Biomarker in CHAARTED Trial Subset - Mark Markowski
OASIS Project Highlights the Survival Benefits of Rapid PSA Decline with Apalutamide in Prostate Cancer - Benjamin Maughan
Integrating Genetic Variants and Clinical Factors for Improved Prostate Cancer Prognostication - Susan Halabi
COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection - Phillip Koo
Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial - Fred Saad
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Current Landscape and Future Directions - Matthew Galsky & Neal Shore
CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li
Prostate Cancer Knowledge and Screening Barriers in Northern Tanzania: A Community-Based Study - Blandina Mmbaga & Nicholas Ngowi
Apalutamide for Preventing Bladder Cancer Recurrence: A Proof-of-Principle Trial - Edward Messing
UCHL1: A Potential Biomarker and Therapeutic Target for Neuroendocrine Prostate Cancer - Tanya Stoyanova
Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care Systems - Isla Garraway
Escalation Strategies for Suboptimal PSA Decline in mHSPC - Mary-Ellen Taplin
Testosterone Recovery After ADT: Timing, Predictive Factors, and Clinical Implications - Pierre Blanchard
Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence - Daniel Spratt
COBRA Trial Shows Promise for 64Cu-SAR-bisPSMA PET in Biochemical Recurrence - Neal Shore
Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie
Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis
Risk Classification for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Using Machine Learning Based Predictions - Beyond the Abstract
The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo
Balancing Bladder Preservation with Effective Treatment in Cancer Care - Petros Grivas
Treatment Options for Advanced Urothelial Cancer Post-EV-302 - Shilpa Gupta & Karima Oualla
Leveraging AI Biomarkers to Navigate the Evolving Landscape of Bladder Cancer Treatment - Stephen Williams
BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson
VA BRAVO 2 Study: Blue Light Cystoscopy Improves Outcomes in NMIBC Patients in Equal Access Setting - Stephen B Williams
Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mark Tyson
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer AUA/SUO Guideline - 2024 Amendment - Jeffrey Holzbeierlein
The Adrenal Permissive HSD3B1 Allele: A Decade-Long Journey from Initial Discovery to Proven Clinical Significance in Prostate Cancer - Nima Sharifi
Navigating the Shift to Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer: Key Considerations for Clinicians - Cora Sternberg
Darolutamide Outcomes in European Patients with Metastatic Hormone-Sensitive Prostate Cancer from the ARASENS Trial - Bertrand Tombal
Preclinical Study Evaluates Enfortumab Vedotin and Sacituzumab Govitecan with Radiation for Bladder Cancer - Kent Mouw
Local Therapy in mHSPC: Who Does Really Benefit? - Alberto Bossi
Genomic Tumor Correlates of Response to Trimodal Therapy for Muscle-Invasive Bladder Cancer - Sophia Kamran
The Impact of the EMBARK Trial on Treatment Decisions in High-Risk Biochemical Recurrent Prostate Cancer - Neal Shore
The Future State of Race & Ethnicity in Urology: Urology Workforce Projection from 2021-2061 - Efe Chantal Ghanney Simons & Ashley Appleton
A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy - Beyond the Abstract
Novel 18-Gene Urine Test Improves Detection of Clinically Significant Prostate Cancer - Jeffrey Tosoian
Patient-Driven Outcomes in the CISTO Trial for High-Grade Non-Muscle Invasive Bladder Cancer - Angela Smith & John Gore
Non-Metastatic Castration-Resistant Prostate Cancer in the Era of PSMA PET Imaging - Aaron Berger
Maximizing Survival in Metastatic Hormone-Sensitive Prostate Cancer: The Role of Triplet Therapy - Kelvin Moses
Teamwork and Trust: Keys to Seamless Prostate Cancer Care Across Specialties - Paul Eber & Brad Somer
Best Practices for Successfully Implementing Triplet Therapy in mHSPC - Christopher Pieczonka
Treating Metastatic Hormone-Sensitive Prostate Cancer: Beyond Counting Metastases - Karim Fizazi
Advancements in Cutting-Edge SABR Therapy for Oligometastatic Kidney Cancer - Shankar Siva
Patient Selection for Radioligand Therapy: Case Study Discussion - Amir Iravani & Evan Yu
Managing Nonmetastatic Castration-Resistant Prostate Cancer - Zachary Reardon
Topical Estrogen Therapy in Preventing Recurrent UTIs in Women - Rachael Sussman, Charlotte Houston with Ruchika Talwar
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Sequential Gemcitabine and Docetaxel Shows Promise for Intermediate-Risk NMIBC - Vignesh Packiam
Intravesical Gemcitabine-Docetaxel Shows Durable Response in Recurrent High-Risk NMIBC After BCG - Mark Preston
Age Alone Should Not Preclude BCG Therapy in NMIBC - Ashish Kamat
Understanding BCG Unresponsive NMIBC: Patient Perspectives, Treatment Options, and Clinical Guidance - Gautam Jayram
Novel Computational Approach Identifies NME2-MYC Axis as Biomarker and Therapeutic Target in Enzalutamide-Resistant CRPC - Antonina Mitrofanova
Understanding Risk Stratification in Non-Muscle Invasive Bladder Cancer: Applying AUA Guidelines in Clinical Practice - Neal Shore
The Impact of Screening Practices for Black Men - Leanne Woods-Burnham
Combining Pembrolizumab and BCG Immunotherapies: The KEYNOTE-676 Trial in High-Risk NMIBC - Neal Shore
ARAMON Trial: Darolutamide Monotherapy and Testosterone Levels in Biochemically Recurrent Prostate Cancer - Andrew Laccetti
Advancing Personalized Medicine: Examining Trop2 as a Biomarker to Stratify Prostate Cancer Patient Risk - Tanya Stoyanova
COMBAT Trial Yields Promising Results for Bipolar Androgen Therapy Plus Nivolumab in Metastatic Castration-Resistant Prostate Cancer - Mark Markowski & Emmanuel Antonarakis
The Use of Imaging in Staging Localized Prostate Cancer: A Case Study on High-Risk Localized Prostate Cancer - Zachary Klaassen
Treatment Options Expand for BCG Unresponsive Bladder Cancer - Mark Tyson
The Southern California Research Forum: Advancing GU Cancer Care - Monty Pal & Rana McKay
PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mark Tyson
Patient Selection for PSMA Radioligand Therapy - Ephraim Parent
Distinguishing True and False Positives on PSMA PET Scans "Presentation" - Courtney Lawhn Heath
Access to Cutting-Edge Therapies and Clinical Trials in the VA- Matthew Rettig
Predictive Markers in Metastatic Prostate Cancer: Insights from the VISION Trial - Oliver Sartor
Radioligand Therapy's Role in Treating mCRPC - Oliver Sartor
Highlights: UCLA/UCSF Inaugural PSMA PET and RLT Conference - Jeremie Calais
Distinct Mesenchymal Cell States Mediate Prostate Cancer Progression - Massimo Loda
Access and Utilization of Healthcare by Adults with Spina Bifida - Lindsay Hampson & Alejandro Lopez
Comparing Cost-Effectiveness of Surgery, Radiation, and Chemo for Seminoma - Daniel Joyce
Testicular Cancer Survivors Find Community and Healing Through Foundation and Patient Summit - Connor O'Leary & Charles Freeman McCluskey
Leaders Establish Consensus Criteria for High-Risk Bladder Cancer Trials, Journal Club - Rashid Sayyid & Zachary Klaassen
Reviewing Evidence on Bone Health and Future Directions in Updated Prostate Cancer Guidelines, Journal Club - Rashid Sayyid & Zachary Klaassen
Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
Operationalizing Blue Light in Your Practice - Gautam Jayram
Chinese Subgroup Analysis Reveals Both Similar and Distinct Responses to Novel Darolutamide Combination Therapy - Yao Zhu
Socioeconomic Disparities Drive Alarming Racial Gaps in Kidney Cancer Patient Survival Rates - Nirmish Singla
Novel Research Illuminates How CXCR7 Protein Interactions Promote Growth of Neuroendocrine Prostate Cancer - Jindan Yu
How Chemotherapy Drives Metastasis By Causing Tumor Cells to Become Significantly More Mobile - Sarah Amend
Deciphering Prostate Cancer: How Genomic Biomarkers are Shaping Treatment Decisions - Paul Nguyen
Novel Gene Therapy Shows Efficacy and Tolerable Safety Profile for Patients with Treatment-Resistant Bladder Cancer - Trinity Bivalacqua
Exploring the Multifaceted Role of a Medical Oncologist in Advanced Prostate Cancer Care and Management - Alicia Morgans
How AI and Machine Learning Are Revolutionizing Prostate Cancer Diagnosis - Tamara Lotan
STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly
Genetic Testing Reveals Treatment Opportunity and Disparity in Advanced Prostate Cancer - Colin Pritchard
INDICATE Trial Seeks to Clarify Role of PET Scans in Prostate Cancer Recurrence - Neha Vapiwala
The Complex Web of SPOP Mutations and STING1 Signaling in Prostate Cancer - Patrick Pilié
Innovative Prostate Cancer Therapy Insights Unveiled in ESMO 2023 Meeting - Alan Bryce
The LITESPARK-013 Trial and Belzutifan's Optimal Dose for Treating Metastatic Renal Cell Carcinoma - Neeraj Agarwal
The ARASTEP Study: Evaluating the Treatment of Biochemically Recurrent Disease in nmHSPC Patients- Alicia Morgans
AKT Inhibitors – Targeting PI3K/AKT/MTOR Signaling Axis - Cora Sternberg
Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming
Broadening Treatment Horizons with CDK4/6 Inhibitors from Breast to Prostate Cancer - Rana McKay
Bone Health Management for Advanced Prostate Cancer - Fred Saad
Tumor Heterogeneity Selective Pressure – Why We Need New Targets? - Oliver Sartor
Unlocking Precision Care: Germline & Somatic Literacy in Prostate Cancer - Elisabeth Heath
Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi
PARP Inhibitors: Targeting DNA Repair Pathways - Neal Shore
The Biological Basis of Metastatic Prostate Cancer – The Unmet Medical Need for New Targets and Novel Treatment Pathways - Dan George
The Critical Intersection of Androgen Receptor Pathways and Cell Cycle Regulation in Prostate Cancer Therapy - Rana McKay
The Current Treatment Landscape in Metastatic Hormone-Sensitive Prostate Cancer - Andrew Armstrong
PSMA PET as a Biomarker for Advanced Prostate Cancer - Oliver Sartor
2023 Key Learnings in mCRPC Treatments – Alicia Morgans
Treatment Decision Making in mHSPC: The Medical Oncologist and Patient “What the Patient Needs to Know” About this Disease and Treatment Options? - Brenda Martone
Treatment Decision Making in mCRPC: The Urologist and Patient “What the Patient Needs to Know” About His Disease and Treatment Options? - Brenda Martone
Multidisciplinary Approach in the Treatment of Metastatic Prostate Cancer - Robert Dreicer
Correlation and Validation of Gene Expression Classifiers in Prostate Cancer: A Large-Scale Study - Daniel Spratt
The Promise, Potential, and Practicality of Cxbladder in Modern Urologic Oncology - Mark Tyson, II
PSMAfore Study Unveils Game-Changing Results for Prostate Cancer Treatment - Oliver Sartor
A Faith-Based Approach to Prostate Cancer Screening and Clinical Trial Recruitment - Pastor Daniel Simmons
Prostate Cancer Drug Costs: A Complex Landscape of Out-of-Pocket Expenses - Benjamin Pockros
Innovation in Oncology Drug Pricing: A Comparative Study of Savings Potential - Ruchika Talwar & Brian Cortese
Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross
Enfortumab Vedotin Combination Therapy and Response Rates - Jonathan E. Rosenberg
The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mCRPC - Susan Halabi
Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis - Jason Efstathiou & Alexandre Zlotta
Choosing JELMYTO®: A Patient's Journey Through Less Invasive Upper Tract Urothelial Carcinoma Treatment - Tom Murphy
Beyond BRCA-1 and 2: The Impact of the TALAPRO-2 Study on Prostate Cancer Care - Cora Sternberg
Exploring Acupuncture's Potential to Mitigate BCG Therapy Side Effects: A Phase I/II Trial - Sarah Psutka
Personalizing Prostate Cancer Therapy Using AI-based Predictive Biomarkers - Paul Nguyen
Exploring Erdafitinib: A Breakthrough in Non-Muscle Invasive Bladder Cancer Treatment - Siamak Daneshmand
Personal Passion Fuels Progress: Unraveling Prostate Cancer Aggressiveness in Black Men - Leanne Woods-Burnham
Improving Bladder Cancer Treatment: An Insight into Vanderbilt's Innovative BCG Clinic - Meredith Donahue & Tara Cumming
Enhancing Patient-Centered Communication in Small Renal Mass Management - Kathryn Hacker Gessner
Breaking Barriers in Urologic Research: Tackling Health Disparities and Collaborative Solutions - Cheryl T. Lee
Promoting Diversity and Empowering Black Urologists: The R. Frank Jones Urological Society - Linda L. McIntire
Addressing Challenges in Bladder Cancer Surgery: Enhancing Patient Outcomes and Preparing for Recovery - Sarah Psutka
Journal of Urology Open Plus - Revolutionizing Access and Innovation in Urology Research - John W. Davis
Pembrolizumab's Impact on Cystectomy-Free Survival in BCG Unresponsive Bladder Cancer from the KEYNOTE-057 Trial - Girish Kulkarni
Full Data Analysis of the Biology and Performance of Pre- and Post-Pembrolizumab VI-RADS for Predicting Pathological Response in MIBC: Insights from a Comprehensive Clinical Trials Pipeline - Andrea Necchi
Improving Primary Prostate Cancer Diagnosis Through Risk Stratified Screening: a European Perspective - Sigrid Carlsson
Combining Belzutifan Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma, Exploring Novel Therapy Options - Toni Choueiri
Advancing Treatment for Non-Clear Renal Cell Carcinoma: Insights and Future Directions (PAPMET & PAPMET 2) - Benjamin Maughan
Debating Treatment Options for Very High-Risk Non-Muscle-Invasive Bladder Cancer: BCG vs. Radical Cystectomy - Morgan Rouprêt & Laura Mertens
Risk Assessment in Localized Prostate Cancer - Insights from Real-World Data and SEER Registry - Jim Hu
Insights into the AUA Guidelines for Upper Tract Urothelial Carcinoma: Standardizing Diagnosis and Treatment for Better Patient Outcomes - Jonathan A. Coleman
ProtecT Trial Reveals New Insights for Prostate Cancer Treatment: Implications for Low-Risk vs. High-Risk Patients - David Penson
15-Year Follow-Up of the ProtecT Trial: Discussing Results and Changes in Prostate Cancer Management, The ProtecT Trial - Oliver Sartor
PSMA-Targeted Radioligand Therapy and Liquid Biopsy Characterizing PSMA Expression in Men with Metastatic Castration-Resistant Prostate Cancer - Andrew Armstrong
Active Surveillance: Optimizing the Quality of Life in Men with Localized Prostate Cancer - Preston Sprenkle & Randy Vince
Targeting the HLA-E/NKG2A Axis to Overcome BCG Resistance in NMIBC, BCAN Translational Clinical Trial Award - Amir Horowitz
Functional and Quality-of-Life Impacts of Prostatectomy, Radiotherapy, and Active Monitoring: Patient-Reported Outcomes from the ProtecT Trial, Journal Club - Rashid Sayyid & Zachary Klaassen
Artera Multi-Modal AI Platform - Guiding Treatment Decisions in Men with Prostate Cancer - Andre Esteva & Felix Feng
Novel Antiandrogens Added to ADT Improves Outcomes in a Subset of High Risk Prostate Cancer Patients - Paul Ngueyn
Beyond the NCCN Localized Prostate Cancer Risk Category: The MMAI Prognostic Risk Stratification Model - Jonathan Tward
Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer - Daniel Spratt
The Clinical Benefits of Blue Light Cystoscopy in the Ambulatory Surgical Centers - Neal Shore
Safety and Disease Related Outcomes of mCRPC Patients Who Were Treated with Radium-223 Then 177Lu-PSMA (RALU) - Neal Shore
Stockholm3 Tests to Inform Risk Stratification before MRI and Targeted Biopsies in the Prostate Cancer Screening Setting, Journal Club - Zachary Klaassen
Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad
MRI-Guided vs CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer, The MIRAGE Randomized Clinical Trial Journal Club - Zachary Klaassen
The Role of Awareness and Support in Elevating Women in Science - Kristen Scarpato & Svetlana Avulova
Artificial Intelligence Transformative in Prostate Cancer Patient Care - Felix Feng
Who is ARTERA? - Andre Esteva
Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley Ross
Prostate Cancer Foundation Establishes Expert Health Equities Panel Creating Prostate Cancer Screening Guidelines for Black Men in the US - Michael Milken, Isla Garraway, & Kneeland Youngblood
Evolving Intermittent Catheter Technology: Review of Materials - Diane Newman
Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study - Emmanuel Antonarakis
Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi
PSMA PET Scan Imaging in Prostate Cancer - Ashley Ross
PSMA PET Imaging Hot Topics - Neal Shore & Jason Efstathiou
Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard
A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore
CAR T and Cellular-Based Therapies - Vivek Narayan
The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore
Timing of Radical Cystectomy in BCG Unresponsive Disease - Patrick Hensley
A Novel Imaging Modality, FAP Imaging for Patients with Bladder Cancer - Vadim S. Koshkin
Women in Urologic Oncology - Anne K. Schuckman
Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans
Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff
Clinical Trial Endpoints in the Adjuvant Setting for Renal Cell Carcinoma and Urothelial Cancer - Andrea Apolo and Pavlos Msaouel
The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff
Bladder Cancer Highlights - Stephen Williams
APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu
Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans
Extending Prostate Genetic Awareness, Navigation and Delivery for Genetic Testing in Males of African American Decent - The EXPAND Network, 2021 PCF-Pfizer Global Health Equity Challenge Award - Veda Giri
Immune Checkpoint B7-H3 - APCCC 2022 - Emmanuel Antonarakis
Optimal Sequencing - Should It Include Radium Given Lutetium? - Joe O'Sullivan
EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer – Jonathan E. Rosenberg
The Phase III PROpel Trial in mCRPC, A Biomarker Analysis and the Detection of Mutations in HRR Genes - Noel Clarke
Trends in Incidence of Metastatic Prostate Cancer in the US - Christopher Wallis & Zachary Klaassen
A Urologist's Perspective on the PROpel Trial, Olaparib and Abiraterone versus Abiraterone Alone, in the First-Line Metastatic Castration-Resistant Prostate Cancer Setting - Neal Shore
An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt Attard
Smarter Screening In Prostate Cancer - Sigrid Carlsson
CheckMate 214: A Deep Dive into Ipilimumab and Nivolumab for Advanced Renal Cell Carcinoma - David Cella
Evaluating the Impact of Variant Histology Pathologic Diagnosis on Survival Outcomes in Patients with Upper Tract Urothelial Carcinoma - Wesley Yip
Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of Brain and Mood? Presentation APCCC 2022 - Charles Ryan
The Impact of Variant Histology on the Management of Patients with Bladder Cancer - Mario Fernandez and Michael A. O’Donnell
Upper Tract Urothelial Carcinoma Highlights - Nima Almassi
Tumor Board Reviewing PSMA PET in the Care of Patient with Gleason 4+4=8 GG 4, 6 Cores on Left, Gleason 4+3=7 GG, 6 Cores on Right Prostate Adenocarcinoma, Session 1 Case 4 - H Jacene, A Kibel, P Nguyen & A Morgans
Management of pN1 Prostate Cancer (Including Systemic Therapy) APCCC 2022 Presentation - Derya Tilki
Tumor Board Reviewing PSMA PET in the Care of Patient with Gleason 4+5=9, GG 5 Prostate Adenocarcinoma, with an Intraductal Component Session 1 Case 1- H Jacene, A Kibel, P Nguyen & A Morgans
Disadvantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Alberto Briganti
Advantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Michael Morris
M0 CPRC: Overview of Treatment Options APCCC 2022 Presentation - Eleni Efstathiou
Biochemical Recurrence After Definitive Radiotherapy of the Prostate – What Are the Local Treatment Options? APCCC 2022 Presentation - Jochen Walz
Who Needs Systemic Treatment With Salvage Radiotherapy? APCCC 2022 Presentation - Brandon Mahal
How Can Treatment Be Individualized By Using Genomic Classifiers? APCCC 2022 Presentation - Felix Feng
Imaging Directed Treatment for Biochemical Recurrence APCCC 2022 Presentation - Nicholas James
Who Needs Early Salvage RT and Who Needs Adjuvant RT in 2022? APCCC 2022 Presentation - Kosj Yamoah
Management of Clinical N1 Prostate Cancer (Including Systemic Therapy) APCCC 2022 Presentation - Darren Poon
Are We Ready to Change Management Based on Next-Generation Imaging? No APCCC 2022 Presentation - Nicolas Mottet
Are We Ready to Change Management Based on Next-Generation Imaging? YES: APCCC 2022 Presentation - Jason Efstathiou
A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore
Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal
Darolutamide Approved for Patients with mHSPC - Charles Ryan
The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta
Deciding Against Active Surveillance: How Genomic Testing Impacted Treatment Decision-Making Among a Predominantly African American Population - Peter Gann and Adam Murphy
BRCAAway - a Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects - Maha Hussain
How Genomic Testing Impacts NCCN Risk Classification of Black Men with Low and Intermediate Risk Prostate Cancer - Andrew Winer
Impact of Next Generation Imaging: What Is the Optimal (Current) Tracer for PET-Based Imaging for Staging Presentation - Ken Herrmann
First Standardized Framework Measuring PSMA PET/CT Response in Metastatic Castration‑Resistant Prostate Cancer - Wolfgang Fendler and Andrei Gafita
The 6th Global Summit On Precision Diagnosis and Treatment Of Prostate Cancer - Faina Shtern, The AdMe Tech Foundation
Rationale for the Use of Decipher® RP Genomic Classifier to Inform Treatment - Ashley Ross
The Use of the Decipher® Biopsy Test Prior to Prostatectomy - Ashley Ross
PSA Directed Treatment for BCR APCCC 2022 Presentation - Neha Vapiwala
The EMBARK Study: A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy - Stephen Freedland
Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo
Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101 in the OLYMPUS Trial - John Gore
Decipher® Biopsy and Decipher® for Prostatectomy in Clinical Practice- Ashley Ross
Multidisciplinary Team Approach to Treatment with Radium-223 for mCRPC - Brenda Martone
Optimal Sequencing and Patient Selection for Radium-223, A Nuclear Medicine Perspective - Phillip Koo
Patient Selection for Treatment with Radium 223 - Tanya Dorff
Supporting Patients Receiving Radium-223 for mCRPC - Fred Saad
Combination Treatment Strategies with Radium-223 for mCRPC - Michael Morris
Management Trends & Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma, the USC Experience - Anirban Mitra
Comparative Effectiveness of Neoadjuvant Chemotherapy In Bladder And Upper Urinary Tract Urothelial Carcinoma - Jeffrey Holzbeierlein
Preventing Recurrence of Urothelial Carcinoma in Patients with Upper Tract Carcinoma - Aditya Bagrodia
Integrating 177Lu-PSMA-617 in Clinical Practice - Oliver Sartor
Incorporating Molecular Testing into Clinical Practice for Prostate Cancer - Elena Castro & Colin Pritchard
Convatec GentleCath™ Glide No-Touch Catheters - Diane Newman
Uncoated Catheters - Diane Newman
Closed Catheters Systems - Diane Newman
Treatment Sequencing with Radium-223 in Symptomatic Disease - Fred Saad
Depression, Bone Health and Exercise in Prostate Cancer - Fred Saad, Tomasz Beer & Charles Ryan
Incorporating Genomic Testing for Prostate Cancer into Your Practice - Daniel Lin
Self Intermittent Catheters Types - Diane Newman
Surveillance Guidelines for Low-Grade Ta NMIBC Often Not Followed - Stephen Williams
The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo
A Urologist's Perspective On the Integration of Lutetium Into Clinical Practices - Neal Shore
Treatment of Unfavorable Intermediate Risk Prostate Cancer - Ashley Ross, Jason Hafron, and Katie Murray
Mental Health and Impact on Patients with GU Malignancies - Zachary Klaassen
The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore
PARPi Combination Therapy Use in Clinical Practice - Ready for Prime-Time? - Maha Hussain and Fred Saad
Prostate Volume, Baseline Urinary Symptoms, and Their Association with Treatment Choice and Post-Treatment Urinary Function in Men with Localized Prostate Cancer, The CEASAR Study - Daniel Barocas
Introducing the 13th International Uro-Oncology Conference in São Paulo, Brazil - Phillip Koo
13th International UroOncology Congress in Brazil - Fernando Maluf
The Role of Radiotherapy in Prostate Cancer - Icaro Carvalho
Identifying Unmet Needs in the Patient Journey in Prostate Cancer - Alicia Morgans
Beyond PSMA - New Targets in Prostate Cancer - Tanya Dorff
Treatment Considerations in Advanced Prostate Cancer - Bertrand Tombal
Symptomatic and Health Related Quality of Life Benefits With Olaparib in Men With mCRPC Carrying Mutations in the Homologous Recombination Repair Genes, Journal Club - Christopher Wallis & Zachary Klaassen
Systemic Therapy in Patients with a Biochemical Recurrence in Prostate Cancer Latin America - Fabio Schutz
The Benefit of ADT Treatment Intensification With Radiotherapy in Localized Prostate Cancer – Dan Spratt and Amar Kishan
Metastases Directed Therapy and Radiation in Oligometastatic Disease Patients - Robson Ferrigno
Future Perspectives in Prostate Imaging in Developing Countries - Ronaldo Hueb Baroni
Barriers and Opportunities in Active Surveillance, HIFU, and Focal Therapy in Latin American Countries - Laurence Klotz
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR - Beyond the Abstract
The Conundrum of Systemic Salvage Therapy at the Time of Salvage Radiation Therapy - Brandon Mahal
Microbiome Research in Bladder Cancer - Laura Bukavina
Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas
The Management of High-Risk Localized Disease and Double Therapy in the mCRPC Setting - Andrey Soares
Novel Approaches in the Management of High-Risk Prostate Cancer - Ray Manneh Kopp
Access to Advanced Treatments in Landmark Advanced Prostate Cancer Clinical Trials - Bertrand Tombal
Evidence Supporting the Use of Urinary Catheters for Intermittent Catheterization - Diane Newman
Lessons Learned in the STAMPEDE Trial - Nicholas James
The Prostate Cancer Foundation Team Science TACTICAL Awards - Howard Soule
Treatment Delay Experiences Among Black and White Men with Prostate Cancer - Bhav Jain & Christopher Dee
Mechanistic Pathway Through Which Saphenous Nerve Stimulation Can Modulate Bladder Function - Paul Yoo
Developing A Novel Neuromodulation Therapy for Treating Overactive Bladder - Anne Agur
Radiotherapy Guided by PSMA PET Molecular Imaging - Juan Galvis Serrano
Preparing for Treatment with 177Lu-PSMA-617 - Kendra Harris
Administering Pluvicto™ - A Patient Shares His Treatment Experience of 177Lu-PSMA-617 - Kendra Harris and Phillip Koo
Higher Rates of Metastatic Disease on PSMA PET for Biochemical Recurrence Risk Groups, Journal Club - Christopher Wallis & Zachary Klaassen
The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra
Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher
The Role of Bladder-Sparing Trimodality Therapy - Sophia Kamran
Biological Pathways in Urothelial Carcinoma - Carissa Chu
Long-Term Safety and Durability to Non-Surgical Treatment Instillation of UGN-101, Mitomycin-Containing Reverse Thermal Gel for Low-Grade Upper Tract Urothelial Carcinoma, Journal Club - Zachary Klaassen and Christopher Wallis
Treating Women with Bladder Cancer and a Community Approach to Navigating a Diagnosis - Jeannie Hoffman-Censits & Elizabeth Guancial
The Upcoming 2022 European International Kidney Cancer Symposium - Samra Turajlic
Hereditary Cancer Risk Assessment For Prostate Cancer Patients - Neal Shore
The Impact of Imaging and Therapeutics Advances in Nonmetastatic Castration-Resistant Prostate Cancer - David Penson
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients with High-Grade Upper Tract Urothelial Carcinoma - Wesley Yip
Radiation Safety and the Integration of Pluvicto™ (177Lu-PSMA-617) in Treatment of mCRPC- Kendra Harris
Looking Forward to the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 - Aurelius Omlin
Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne
Health-Related Quality of Life- The ENZAMET Trial - A UroToday Journal Club –- Christopher Wallis & Zachary Klaassen
Clinical Implementation of Pluvicto™ (177Lu-PSMA-617) - Michael Morris
The APCCC 2022 - A Hybrid Meeting April 28 - 30 - Silke Gillessen
Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg
Symptoms Related to Bone Metastasis in Men Receiving Lutetium-177 PSMA-617 for Prostate Cancer - Brian Gonzalez
Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC - Oliver Sartor
A Real-World Study of PSA Response in Black and White Chemotherapy-Naive Prostate Cancer Patients Treated With Enzalutamide - Alicia Morgans
Significant Improvement With Continuous Enzalutamide in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer – Axel Merseburger
Pluvicto The First Targeted Radioligand Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer FDA Approved - Charles Ryan and Alicia Morgans
Molecular Biomarkers in Upper-Tract Urothelial Carcinoma - Janet Kukreja
ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Journal Club - Christopher Wallis & Zachary Klaassen
Associations of Adverse Pathology With 20 Year Risk of Distant Metastasis and Prostate Cancer Specific Mortality - Michael Brooks
ARASENS Trial Significantly Improves Overall Survival with Darolutamide in Combination with ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith
The Effect of Durvalumab and Olaparib on Prolong Progression-Free Survival As First-Line Therapy in Platinum-Ineligible Patients With Unresectable Urothelial Carcinoma - The BAYOU Study – Jonathan Rosenberg
Treatment and Survival Differences in Patients With Urothelial Vs. Nonurothelial Bladder & Upper Tract Carcinomas - Jeanny Aragon-Ching
Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-Years After Radical Prostatectomy - Eric Klein
The Next Wave of Novel Radiopharmaceuticals - Shahneen Sandhu
Advanced Prostate Cancer Practice Informing Data Presented at ASCO GU 2022 - Oliver Sartor
Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng
Appropriate Use Criteria for PSMA PET Imaging - Hossein Jadvar
KEYNOTE-564 30-Month Follow-Up of Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma - Toni Choueiri
The Efficacy and Safety of Olaparib + Abiraterone in the First-Line mCRPC Setting PROpel – Fred Saad
DS8201-a-U105 Trial of Trastuzumab Deruxtecan With Nivolumab in Patients With Urothelial Carcinoma – Matt Galsky
Validation of Performance of the Decipher® Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi
Next-Generation Sequencing: Discussing Results with Patients - Bishoy Faltas
PSMA PET/CT Imaging Indications in Prostate Cancer - Neal Shore & Oliver Sartor
Research in Biomarkers for Bladder Cancer - The BCAN Young Investigator Awards - Benjamin Miron
Quality of Life for Patients Undergoing Radical Cystectomy - Bernard Bochner
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
Protecting Our Planet: The 15th Asian Financial Forum - Michael Milken
Perioperative Optimization for Patients Undergoing Radical Cystectomy – Sarah Psutka
Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award Program - Elizabeth Plimack
The Impact of Decipher® Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.
Financial Toxicity Among Patients with Bladder Cancer - Deborah Kaye
From the Stage to the Clinic and Back: Medicine and Burnout - Stuart H. Bloom
Bladder Cancer: A Practical Guide - Ashish Kamat & Peter Black
NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and Chris Wallis
Demonstrated Underuse of Blue Light Cystoscopy for Bladder Cancer in the United States - Patrick Lewicki
Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan
Resourcing the Patient and Caregivers Prostate Cancer Journey and The Prostate Cancer Foundation - Kneeland Youngblood
Anticipated Data from Transformative Trials at ASCO GU 2022 - Oliver Sartor
Accelerating Research and Development to Save Lives - Esther Krofah
NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff
A Real-World Analysis of Pain Efficacy of Radium-223 Treatment Among Patients With Metastatic Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases – the REASSURE Trial – Celestia Higano
Improving Health Equity and Reducing Disparities in Prostate Cancer Care – Kosj Yamoah
Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor
Management of Small Local Recurrence Low-grade Bladder Tumors with Negative Cytology - Marek Babjuk, Morgan Roupret & Wassim Kassouf
Treatment-Related Regret Among Men With Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen
Understanding Physiological PSMA Biodistribution - Jeremie Calais
Women in Science and The Prostate Cancer Foundation - Amina Zoubeidi
Lifestyle Interventions to Reduce Prostate Cancer Risk - Lorelei Mucci
Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer - Heather Payne
The World Bladder Cancer Patient Coalition Launches Bladder Cancer Patient Survey
Ongoing Clinical Trials Evaluating The Efficacy of Targeted Radioligand Therapy - Shahneen Sandhu
Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Men With DDR Gene Mutations, the TALAPRO-3 Trial in mCSPC – Neeraj Agarwal
BiTE Immune Targeted Therapy in mCRPC - Tanya Dorff
The Dark Side of PSMA: Pitfalls, Limits, and ADT - Matthias Eiber
NCCN Guideline Review on Prostate Cancer - Epidemiology, Initial Diagnosis, and Life Expectancy of Men With Prostate Cancer: Journal Club – Christopher Wallis & Zachary Klaassen
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack
The Mechanism of PSMA PET for Prostate Cancer - Stefano Fanti and Ken Herrmann
NCCN Guidelines on Prostate Cancer Reviewing Advanced Prostate Cancer Neuroendocrine Disease, Bone and Visceral Metastases, and Treatment Sequencing – Christopher Wallis & Zachary Klaassen
Single-Use Disposable Cystoscopy - Roger Dmochowski, David Chaikin, & Vijay Goli
Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors CABA-GCT - Giulia Baciarello
Observation and Active Surveillance in the NCCN Prostate Cancer Guidelines- Christopher Wallis and Zachary Klaassen
Prospective Analysis of The Effect of Germline Mutations on Outcomes for mCRPC Patients Treated With Radium-223 (PRORADIUM) – Elena Castro
PSMA-targeted PET Imaging of Prostate Cancer - A Primer for Urologists - Michael Gorin
Symposium Discussion on PSMA-Targeted PET Imaging and Interpretation - What Urologists Need to Know
Financial Toxicity in Bladder Cancer—A Mixed Methods Study of Two Diverse Patient Populations - Sumeet Bhanvadia
PSMA-Targeted PET Imaging Metastatic Disease, Response Assessment, Future Directions, and Read Paradigms - Steven Rowe
Real-World Data in Second-Line Treatment Progressing mCRPC – Oliver Sartor
Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio
Antegrade Endoscopic Upper Tract Approaches - Ryan Hsi
Sabizabulin in Men with Metastatic Castration Resistant Prostate Cancer - Mark Markowski
A Trial of VERU-100 for the Treatment of Advanced Prostate Cancer – Ronald Tutrone
NCCN Guidelines on Prostate Cancer Genetics - Christopher Wallis & Zachary Klaassen
Tumor Board Reviewing Locally Advanced pT3N1M0 Prostate Cancer - CASE 4
Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke
Upper Tract Urothelial Carcinoma - Clinical Case Management in High-Risk Disease - Sima Porten
Therapy Resistance Identified in Circulating Tumor Cell Morphologic Sub-Types Present Prior to Treatment in the CARD Trial - Cora Sternberg
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
NCCN Guidelines on Prostate Cancer - A Focus on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer - Christopher Wallis and Zachary Klaassen
NCCN Guidelines on Prostate Cancer: A Focus on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer - Chemotherapeutic Approaches - Christopher Wallis and Zachary Klaassen
The APCCC 2021 Focuses on Key Areas of Advanced Prostate Cancer Management: Newly Diagnosed mHSPC, PSMA in Diagnostics and Therapy and Novel Targets in mCRPC - Silke Gillessen
Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz
Frontline Cabozantinib in Metastatic Collecting Ducts Renal Cell Carcinoma – Giuseppe Procopio
Evaluating the Efficacy of Sabizabulin in The Treatment of Metastatic Castration-Resistant Prostate Cancer – Robert Dreicer
The Efficacy of Enzalutamide + ADT vs Placebo + ADT in Patients Who Received Prior Antiandrogen Therapy in the ARCHES Study – Neal Shore
Delayed Deterioration in Patient Quality of Life, the Impact of Darolutamide on Local Symptoms in the ARAMIS Trial – Neal Shore
Value Based Care in Surveillance of Non-Muscle Invasive Bladder Cancer – Stephen Williams
STAMPEDE Analysis of Abiraterone With or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone In High-Risk Non-Metastatic Prostate Cancer Patients– Gerhardt Attard
A Novel Sublingual Vaccine for Prevention of Recurrent Urinary Tract Infections in Women - J. Curtis Nickel
Relugolix in the Phase 3 HERO Study in Men with mHSPC - Bertrand Tombal
Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo mCSPC – Karim Fizazi
Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi
The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder - Michael A. Weber
Intermittent vs Continuous ADT for Patients A Review of the NCCN Guidelines – Christopher Wallis and Zachary Klaassen
ADT for Castration-Naive Disease A Review of the NCCN Prostate Cancer Guidelines – Christopher Wallis and Zachary Klaassen
The Efficacy of Olaparib in the PROfound Study – Fred Saad
Choice of Urinary Diversion in Patients Undergoing Radical Cystectomy - Peter Black, Jens Bedke, and Hugh Mostafid
Optimal Therapy for Patient with T0 After Neoadjuvant Chemotherapy - Sima Porten, Ananya Choudhury, Paolo Gontero, and Kamal Pohar
Building a Sustainable Radioligand Treatment Clinic – Charlotte Manogue
Impact of Age on Castration Rates from The HERO Study – Michael Cookson
Risk Stratification of Upper Tract Urothelial Carcinoma - Doug Scherr
Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis - Beyond the Abstract
Establishing A Theranostics Clinic for Advanced Prostate Cancer – Kendra Harris and Charlotte Manogue
The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher® Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra
When to Add ADT to Early or Late Salvage Radiation - Dan Spratt
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt
Radium-223 Treatment for Metastatic Prostate Cancer - Ila Sethi
Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo
The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff
Health-Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma in the CLEAR Trial – Bradley McGregor
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
The OAB Clinical Care Pathway Mobile APP - Stephen Kraus
Management and Challenges of Low Grade Upper Tract Urothelial Carcinoma - Surena Matin
F-18-Labeled DCFPyL in Patients With Metastatic Prostate Cancer Undergoing Treatment With ADT – Esther Mena Gonzalez
The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer - BCAN New Discoveries Young Investigator Award - Eugene J. Pietzak
Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu
PCORI-Funded Initiative Evidence Gaps To Guide Future Research on the Use of Active Surveillance for Prostate Cancer – M. Minhaj Siddiqu
The Management of Primary Carcinoma of The Urethra - Reza Mehrazin
18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen
Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone
Differences in the Pattern of and the Response to Treatment Not Just Race - Elisabeth Heath
Defining the Standard of Therapy for First-Line mHSPC - Lisa Horvath
Sexual Function in Women Undergoing Radical Cystectomy, BCAN New Discoveries Young Investigator Award for Patient-Centered Research - Svetlana Avulova
Prognostic Utility of Decipher® Prostate Genomic Classifier in the SAKK 09/10 Phase III Trial - Alan Dal Pra
How I Use Jelmyto™ - Karim Chamie
KEYNOTE-564 Demonstrates Improvement in Disease-Free Survival - A New Standard of Care for High-Risk Kidney Cancer - Rana McKay
177LuPSMA-617 - A New Standard of Care in the Treatment of mCRPC Based on The Phase III VISION Trial Results - Michael Morris
A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher Wallis & Zachary Klaassen
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland
The Diagnostic Performance of PSMA PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY) - Christopher Wallis & Zachary Klaassen
Practical Considerations For the Use of Switch Maintenance Therapy: Avelumab First-Line Maintenance in Locally Advanced or Metastatic Urothelial Carcinoma Journal Club - Christopher Wallis & Zachary Klaassen
PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval - Michael Morris
Results From the IGCCCG Update Consortium in Metastatic Seminoma And Nonseminomatous Germ Cell Tumors – Silke Gillessen
Upper Tract Urothelial Carcinoma - Clinical Case Management – Jonathan Coleman
Assessment and Treatment of Cardiovascular Risk Factors in Veterans with Prostate Cancer - Ravi Parikh and Lova Sun
The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker
Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal
Survivorship in Testicular Cancer - Mary Dunn
Practical Considerations for Administering Avelumab Maintenance in Clinical Practice - Petros Grivas and Neeraj Agarwal
Improved Tumor Visibility, Detection Rate and Reduced Recurrence Rates After TURBT - Siamak Daneshmand and Marek Babjuk
Pembrolizumab in the Real-World Setting for Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG - Arjun Balar
Transitioning Patients to an Oral GnRH Antagonist and Optimizing Patient Outcomes - Brenda Martone
Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak
Facing Pelvic Pain - Elise De
Cabazitaxel is Active in Men with mCRPC with DDR Alterations - Karim Fizazi and Mihaela Aldea
The Cardiovascular Complications of Therapy for Patients with Prostate Cancer - Vivek Narayan
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
The Role and Timing of Urodynamics and Certificate in Urodynamics Virtual Course - Hashim Hashim
177 Lu-PSMA-617 Offers a Promising Treatment for Men with Progressing mCRPC. - Declan Murphy & Michael Hofman
Intensive Androgen Deprivation in High-Risk Biochemically Recurrent Prostate Cancer Patients - Alliance Foundation Trial (AFT19) - Rahul Aggarwal
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt
Nivolumab Plus Docetaxel for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer from CheckMate 9KD Arm B, - Karim Fizazi
Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor
Genitourinary Cancers Symposium 2021 Trials in Progress TROPiCS-04 - Petros Grivas
Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal
Advances from 2020 in the Management of Muscle Invasive Non-Metastatic Bladder Cancer - Bernard Bochner
Surgical Simulator for Laparoscopic Partial Nephrectomy for Renal Cell Carcinoma - Gonzalo Vitagliano
Imaging-Based Prostate Cancer Screening Among BRCA Mutation Carriers - A UroToday Journal Club
NCCN Guidelines Updated for Prostate Cancer M1 Systemic Therapy Based Upon The CARD Trial - Tanya Dorff
The Accidental Journey of Shepherding PSMA PET Imaging in Prostate Cancer to the Clinic in the United States - Thomas Hope
Clinical Implications of the Study Findings from the Radiotherapy Adjuvant Versus Early Salvage ((TROG 08.03/ANZUP RAVES) Trial - Andrew Kneebone and Declan Murphy
Operationalizing Genomic Testing for Clinical Practice In Prostate Cancer - Jason Hafron
The Progress and Promise of Prostate Cancer Treatments in 2020 - Charles Ryan & Alicia Morgans
The Alliance Trial A031801 - RadiCal a Trial of Radium-223 in Patients with Renal Cell Carcinoma, - Rana McKay
First and Only Oral GnRH Receptor Antagonist Orgovyx for the Treatment of Advanced Prostate Cancer - Charles Ryan & Alicia Morgans
68Ga-PSMA-11 Joins FDA-Approved Tools for Management of Prostate Cancer - Thomas Hope
Racial Differences in Genomic Profiling in Prostate Cancer - Brandon Mahal
Discussing the Efficacy and Safety from Results of the Dose Escalation Arm of AMG 160, a Bispecific T-Cell Engager (BiTE) Immune Therapy Targeting PSMA for Metastatic Castration-Resistant Prostate Cancer - Ben Tran, Oliver Sartor, and Neal Shore
BRCA1/2 and Beyond - Molecular Diagnostic Testing and Treatments with PARP Inhibitors for mCRPC - Joaquin Mateo
Preliminary Efficacy of AMG 160 in Metastatic Castration-Resistant Prostate Cancer, Interim Results From the Phase 1 Study - Tanya Dorff
DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt
Overall Survival Data from the Global, Phase 3 ARAMIS Trial in Men with Non Metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi
Cardiovascular Disease and Androgen Axis - Targeted Drugs for Prostate Cancer- Javid Moslehi
Contemporary Treatment Strategies For Androgen Deprivation Therapy In Prostate Cancer - Michael Cookson - Alicia Morgans - Fred Saad & Neal Shore
Changing the Standard of Care in Prostate Cancer with Advances in Nuclear Medicine, PET and Theranostics Symposium - Rob Flavell
Implications for Reducing Disparities in Muscle-Invasive Bladder Cancer - Samuel Washington III
Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Can Be Preselected to Maximize Benefit of Olaparib - Maha Hussain
Interim Results from AMG 160 a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC) - Ben Tran
An Expert Discussion on Gleason 6 (Grade Group 1) Prostate Cancer - Scott Eggener 
Treatment Considerations For Disease Progression After Combination Therapy in mCRPC - Alicia Morgans
The Role of FoundationOne® Liquid CDx in mCRPC - Oliver Sartor
The Dynamic Advancements in Personalized Treatments for Metastatic Urothelial Cancer - Andrea Apolo
The Impact of Patient, Procedural, and Staffing Factors Upon Ureteroscopic Costs - Duane Baldwin
DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao
PSMA-directed Therapy - Scott Tagawa and Michael Morris
JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg
Journal Club on Ureteroscopic Doppler Ultrasonography: Mapping Renal Blood Flow From Within the Collecting System- Evangelos Liatsikos and Roshan Patel
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu
Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma - Alison Birtle & Surena Matin
A Discussion on Implementing the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines - Sam Chang
Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer - Sia Daneshmand & Trinity Bivalacqua
Improving and Optimizing Transurethral Resection of Bladder Tumor (TURBT) Outcomes - Hugh Mostafid
In His Own Voice: His 15-Year Journey with Advanced Prostate Cancer - Steve Poggi
HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore
Rucaparib, A PARP Inhibitor For The Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Wassim Abida
Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen
IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Christopher Sweeney
TheraP: 177Lu-PSMA617 Theranostic vs Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) - Michael Hofman & Ian Davis
Blue Light Cystoscopy with Cysview for Management of Non Muscle Invasive Bladder Cancer - Joshua Meeks
Expanding Access to GU Cancer Care Through Telehealth and Prioritizing Systemic Therapies for Genitourinary Malignancies - Srikala Sridhar
Implications of the Bacillus Calmette-Guérin (BCG) Shortage - Joshua Meeks
Genitourinary Cancer Management During COVID-19 Pandemic Dana-Farber/Brigham and Women’s Cancer Center Proposed Clinical Guidelines - Toni Choueiri
PARP Inhibitors Changing the Standard of Care for Treatment of Metastatic Prostate Cancer (mCRPC) - The PROfound Study
Outcomes from The PROCEED Registry: Survival of African-American and Caucasian Men After Sipuleucel-T Immunotherapy - Oliver Sartor
In Pursuit of Patient-Centered Care - Karen Knudsen
Making Your Treatment Decision - Prostate Cancer Patient Interview with Andy Schwartz
Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith
NCCN Localized Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer
NCCN Metastatic Castration-Resistant Prostate Cancer Patient Treatment Considerations During the COVID-19 Pandemic - Edward M. Schaeffer and Alicia Morgans
Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore
The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran
COVID-19 Impacting GU Cancer Care in New Orleans at Tulane Cancer Center - A. Oliver Sartor
Considerations of GU Cancer Patients Treatments in the New Reality of COVID-19 - Petros Grivas
Moving the Field Forward, Upper Tract Urothelial Carcinoma, The POUT Study - Alison Birtle
Updates on Bladder Cancer Clinical Trials ASCO GU 2020 - Matthew Galsky
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz
CARD Study Demonstrates Cabazitaxel Improves Pain and Health-Related Quality of Life Analysis in Patients with mCRPC - Karim Fizazi
A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar
Advanced Prostate Cancer Clinic: What’s Changing? - Maha Hussain
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris
Darolutamide Treated Patients Maintained Quality of Life in ARAMIS Trial - Fred Saad
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran
Radium-223 in Clinical Practice - Phillip J. Koo
Prospective, Real-World Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients – Oliver Sartor
Genetic Counseling in Prostate Cancer - Brittany Szymaniak
First-line Therapy Options for Metastatic Renal Cell Carcinoma - Tian Zhang
Clinical Trials: Another Treatment Option for Patients - Tom Farrington
Challenges in the Diagnosis and Treatment of UTUC - Peter Black
Clinical Implications of TITAN in mHSPC - Kim Chi and Michael Morris
Real-World Evaluation of Disparities in Prostate Cancer Outcomes - Daniel Spratt
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans
Sharing Clinical Information through Social Media - Todd Morgan & Daniel Spratt
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook - Andrea Apolo
Immunotherapy Across Genitourinary Malignancies - James Gulley
Optimizing ADT in Prostate Cancer Patients - Tom Keane
Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 - Jeremie Calais
Blue Light Cystoscopy for Diagnosis of Bladder Cancer - A Journal Club Review by Badrinath Konety
Results from TRITON2: Treatment of mCRPC with Rucaparib - Alan Bryce
Genetic Evaluation of Hereditary Prostate Cancer - Sanjeev Kaul
A Conversation on Immuno-Oncology in Bladder Cancer - Petros Grivas
Update on Immunotherapy Advances in Renal and Bladder Cancer - Cora Sternberg
A Renewed Analysis of ERA 223 - Fred Saad
High Grade Non-Muscle Invasive Bladder Cancer and BCG Refractory Patient - Josh Meeks
CARMENA: Practice Changing Strategies for Kidney Cancer
Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
Nocturia in the Aging Patient, Assessment and Treatment- Susann Varano
Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng
The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor
Update on Bladder Cancer, Current Trials and Treatments - Bishoy Faltas
Updates in Advanced Urothelial Carcinoma - Highlights from ASCO 2018 - Petros Grivas
Dedication to Multidisciplinary Management of GU Oncology - Alex Kutikov
Lower Urinary Tract Symptoms: Case-Based Discussion with Eric Rovner
Clinical Implications of the Abi Race Study: Interview with Dan George
Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo
Personalization of Therapy to Optimize Outcomes for Men with Prostate Cancer - Interview with Felix Feng
The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons
Defining Bladder Health - Ariana Smith
Geriatric Assessment of Men with Prostate Cancer - Alicia Morgans
New Concepts in ADT- Thomas Keane
Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas
Pathophysiology of Nocturia - Jeffrey Weiss
nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.
Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain
A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - Neal Shore
Changing the Landscape of nmCRPC - The SPARTAN Trial - Eric Small
Radical Prostatectomy for Patients with Oligometastatic Prostate Cancer - Robert Hamilton
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin
Under the Knife, A Book Review with Kelly Parsons
GayBiProstate Study: Expanding Quality of Life and Understanding Sexual Function Post Treatment - Bernard Lee
UPWARD Study - Seizure Rates in Enzalutamide-Treated Men with mCRPC - Susan Slovin
The State of BPS/IC: "The Emperor Has No Clothes" - Christopher Payne

Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives

Phase 2 TheraPb Trial Evaluates a Novel Induction and Maintenance Regimen of 212Pb-ADVC001 Across Three Metastatic Prostate Cancer Indications - Anna Karmann
DARPin-Based Radioligand Therapy Targets DLL3 with Lead-212 for Cancer Treatment - Philippe Legenne
Imaging the Immune System: CD8 T-Cell Tracking for Cancer and Autoimmune Disease - Anna Wu
Lead-212 Radiopharmaceuticals Offer Promise in Targeted Cancer Treatment - Volker Wagner
Covalent Radioligands Advance Precision in Tumor Targeting - Andreas Goutopoulos
Advanced Isotope Therapies Reshape Cancer Care Approaches - Andrew Cavey
Developing Radium-223: From Bone Metastases to Systemic Radiopharmaceuticals - Øyvind Bruland
Radiopharmaceutical Innovations Transforming Cancer Treatment Landscape - Jeffrey Humphrey
Expanding Horizons: Targets and Isotopes in Cancer Theranostics - Martin Pomper
Combining Nuclear Medicine and Immunotherapy for Enhanced Cancer Treatment - Chris Behrenbruch
Understanding Isotopes and Targets Key in Radiopharmaceutical Therapy - Jessica Jensen
Expanding Radiopharmaceuticals for Cancer Treatment: Addressing Supply and Manufacturing Challenges - Charles Conroy
Theranostics Revolution: Shaping the Future of Cancer Treatment - Sergio Calvo
Exploring Actinium-225: Transforming Cancer Treatment with Targeted Radiopharmaceuticals - John Valliant
Lead-212 Radiopharmaceuticals: Advancing Targeted Alpha Therapy in Oncology - Anna Karmann
Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy - John Babich
Advancing Radiopharmaceuticals: Isotopes, Targets, and Challenges - Germo Gericke
Copper-67 (Cu-67 or 67Cu) in Cancer Therapy: Current Developments and Future Potential - Alan Taylor
Advancing Radiopharmaceuticals: From Lead-212 to Pre-Targeting Strategies - Michael Schultz
Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff
Lead-212 Radiopharmaceuticals: Next Frontier in Cancer Treatment - Emanuele Ostuni

High-Risk Non-Muscle Invasive Bladder Cancer

Treatments in Development in NMIBC

CORE-008 Cohort A First Results on Cretostimogene Grenadenorepvec for BCG-Naive Bladder Cancer - Shane Pearce
Cohort P Data from the BOND-003 Study in BCG-Unresponsive Papillary Bladder Cancer - Mark Tyson
24-Month Follow-Up Data from Phase 3 BOND-003 Cohort C Trial - Mark Tyson
CORE-008 Cohort B Investigates Cretostimogene Grenadenorepvec for BCG-Exposed High-Risk NMIBC - Trinity Bivalacqua
Phase 3 Trial Results for Intravesical Cretostimogene Grenadenorepvec in Bladder Cancer - Mark Tyson
Sasanlimab Plus BCG Improves Event-Free Survival in High-Risk NMIBC: First Interim Trial Results, Journal Club - Rashid Sayyid & Zachary Klaassen
CORE-008 Trial Cohort CX: Combining Cretostimogene Grenadenorepvec and Gemcitabine for Bladder Cancer - Trinity Bivalacqua
CORE-008 Cohort B: Cretostimogene for BCG-Exposed NMIBC – Trial Activation & Clinical Goals - Trinity Bivalacqua
BOND-003 Cohort P Results for BCG-Unresponsive Papillary Bladder Tumors - Mark Tyson
CORE-008 Cohort A: Cretostimogene in BCG-Naïve High-Risk NMIBC – Trial Design & Update - Trinity Bivalacqua
BOND-003 Cohort C Trial Results for Cretostimogene Grenadenorepvec in BCG-Unresponsive Bladder Cancer - Mark Tyson
PIVOT-006: Phase III Trial of Creto vs Surveillance in Intermediate-Risk Bladder Cancer - Mark Tyson
MoonRISe-1: Evaluating TAR-210 for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer - Roger Li
Cretostimogene Grenadenorepvec: A Novel Oncolytic Immunotherapy for BCG-Unresponsive NMIBC - Roger Li
CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li
Leveraging AI Biomarkers to Navigate the Evolving Landscape of Bladder Cancer Treatment - Stephen Williams
AI-Based Assessment Tool for Predicting BCG Response in Bladder Cancer Patients - Yair Lotan
PIVOT-006: Phase 3 Trial Comparing Oncolytic Virus Creto vs Observation for Intermediate-Risk NMIBC - Robert Svatek
BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson
Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mark Tyson
Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC: A Discussion on the BOND-003 and CORE1 Trials - Trinity Bivalacqua
Understanding BCG Unresponsive NMIBC: Patient Perspectives, Treatment Options, and Clinical Guidance - Gautam Jayram
PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mark Tyson
BOND-003 Phase 3 Results: Revolutionizing Bladder Cancer Treatment with Intravesical Cretostimogene Grenadenorepvec Monotherapy for High-Risk BCG-Unresponsive NMIBC - Mark Tyson
Cretostimogene Grenadenorepvec Therapy Aims to Fill an Unmet Need in the Bladder Cancer Armamentarium - Robert Svatek
Combining CG0070 Adenovirus Vector with Immune Checkpoint Blockade: Promising Results for BCG Unresponsive Bladder Cancer Patients - Roger Li

Real-World Decision Making for Treating mHSPC: Case Discussions

Genomic Classifier in Prostate Cancer: Intermediate-Risk

Combining PSMA PET and Genomic Risk Assessment in High-Risk Prostate Cancer - Sophia Coraci
Correlation Between Genomic Classifier Scores and Upfront Treatment Selection in Localized Prostate Cancer: A Real-World U.S. Population-Based Cohort Study - Michael Leapman
Treatment Intensification Strategies for High-Risk Prostate Cancer Patients - Aaron Berger
Combining Genomic Classifier and Digital Pathology Artificial Intelligence in Prostate Cancer Risk Stratification - Daniel Spratt
Epidemiology Applied to Focal Therapy in Prostate Cancer: Where do we Stand? - Kae Jack Tay
The Future of Prostate Cancer Risk Stratification and Treatment Planning - Eric Kim
The Future of Prostate Cancer Diagnosis: Combining Non-Invasive Tests for Personalized Care - Eric Kim
Investigating the Relationship Between MRI Findings, Genomic Markers, and Gleason Score - Eric Kim
Precision Risk Assessment in Prostate Cancer: Growing Utility in NCCN Guidelines - Rashid Sayyid & Zachary Klaassen
A Comprehensive Look at Genomic Classifier Performance in Intermediate Risk Prostate Cancer: Insights from the NRG Oncology/RTOG 01-26 Trial, Journal Club - Rashid Sayyid & Zachary Klaassen
Risk Assessment in Localized Prostate Cancer - Insights from Real-World Data and SEER Registry - Jim Hu
The Use of Genomics in Unfavorable Intermediate-risk Prostate Cancer - David Morris
The Molecular Biology of Prostate Cancer - Christopher Barbieri
Treatment of Unfavorable Intermediate Risk Prostate Cancer - Ashley Ross, Jason Hafron, and Katie Murray
The Benefit of ADT Treatment Intensification With Radiotherapy in Localized Prostate Cancer – Dan Spratt and Amar Kishan
Validation of Performance of the Decipher® Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski
The Impact of Decipher® Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt

Latest Videos

Lutetium-177 PSMA-617 Therapy Across the Prostate Cancer Spectrum: Mechanism, Formulation, and Future Directions - Phillip Koo
More Than Just Size: the Search for Accurate Stone Volume Assessment "Presentation" - Seyed Amiryaghoub Lavasani
Outcomes in the Management of Complex Renal Cysts: Balancing Overtreatment, Cost, and Radiation Exposure "Presentation" - Helen Gao
CAN-2409 in Localized Prostate Cancer: Protocol, Outcomes, and Patient Perspective - Mark Garzotto & Tom Hulsey
Dual Laser Lithotripsy: A New Concept for More Efficient Stone Fragmentation "Presentation" - Helen Gao
The Effect of Intravenous Administration of a Rho-Kinase Inhibitor on Porcine Ureteral Distensibility "Presentation" - Aymon Ali
Scaffold-Guided Regenerative Bladder Augmentation Using Medical Grade Titanium Foil in the Porcine Bladder: Initial Results "Presentation" - Aymon Ali
Intrarenal Antibiotic Irrigation During PCNL Reduces Postoperative Infections and Eliminates Sepsis in High-Risk Patients: A Matched Cohort Study "Presentation" - Kriselle Madamba
Comparative Analysis of a Novel Air-Bubble Guided Percutaneous Access Technique Against Traditional Fluoroscopic Techniques "Presentation" - Ian Ong
Characterization of Intrarenal Temperature and Pressure During Ex Vivo High-Energy Thulium Laser Lithotripsy "Presentation" - Kantapon Tangwiwat
CORE-008 CX Early Efficacy and Tolerability Data - Aaron Berger
Findings from the Bladder Burden Survey: Patient Perspectives on Communication, Trust, and Quality of Life in Bladder Cancer - Meri-Margaret Deoudes
Non-Surgical Management of Non-Muscle Invasive Bladder Cancer: Surveillance, Chemoablation, and Office-Based Approaches - Katie Murray
PROTEUS Trial: Neoadjuvant Apalutamide and Androgen Deprivation Therapy in High-Risk Localized Prostate Cancer - Mary-Ellen Taplin
Hydrogel Spacer Placement for Prostate Radiotherapy: A Urology Residency Training Experience - Zachary Klaassen
Randomized Trial of Blue Light Versus White Light TURBT with Urinary Tumor DNA Testing - Armine Smith & Meghan McNamara
MEVPRO-3 Trial: Enzalutamide With or Without Mevrometostat in Metastatic Hormone-Sensitive Prostate Cancer - Neeraj Agarwal
MEVPRO-1 and MEVPRO-2 Trials of EZH2 Inhibitor Mevrometostat in mCRPC - Neeraj Agarwal
Radioligand Therapy and Patient Selection Criteria for Lu-PSMA-617 - Phillip Koo
CAN-2409 with Valacyclovir and Radiation for Localized Prostate Cancer - Mark Garzotto
Moving Beyond Repeat TURBT in Recurrent NMIBC - John Sfakianos

Recent Conference Coverage

  Conference Highlights Written by Physician Scientists
SNMMI 2026
View all SNMMI 2026 coverage
ASCO 2026
View all ASCO 2026 coverage

Recent Physician-Scientist Review Articles

  State of the Evidence Review Articles
Advanced Bladder Cancer
View all Advanced Bladder Cancer
PSMA-Targeted Therapy
View all PSMA-Targeted Therapy

Transformative Evidence

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information

ARANOTE

Presented by Zachary Klaassen, MD, MSc
The 2026 Southeastern Section of the AUA Annual Meeting featured a presentation by Dr. Zachary Klaassen of a post hoc analysis from the phase 3 ARANOTE trial evaluating darolutamide plus androgen-deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with outcomes stratified by disease volume.

Genomic Biomarker Testing

Presented by Pedro C. Barata, MD, MSc
The 2026 ASCO GU Annual Symposium was host to a prostate cancer poster session. Dr. Pedro Barata presented an analysis of real-world patient characteristics and treatment patterns among metastatic castration-resistant prostate cancer (mCRPC) patients treated with talazoparib + enzalutamide in the United States.

Trials in Progress

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information

MEVPRO-3 Trial

Presented by Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO, discussed MEVPRO-3, a phase III trial of mevrometostat + enzalutamide versus placebo + enzalutamide in mCSPC. Enhancer of zeste homolog 2 (EZH2) enzymatic activity plays a crucial role in prostate cancer progression. Mevrometostat, an oral potent and selective EZH2 inhibitor, may synergize with androgen receptor pathway inhibitors to delay androgen receptor pathway inhibitor resistance.

MEVPRO-1 & 2 Trial

Presented by Nobuaki Matsubara, MD
The 2026 ASCO GU cancers symposium held in San Francisco, CA, was host to the Poster Session A: Prostate Cancer. Dr. Nobuaki Matsubara presented Poster 195: Efficacy and safety of mevrometostat in combination with enzalutamide in patients with mCRPC: Data from a phase 1 study.